Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
- Conditions
- Chemotherapy-induced Neutropenia
- Interventions
- Registration Number
- NCT03102606
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Brief Summary
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15.
\*Study is officially closed on 08 Feb 2021\*
- Detailed Description
Arm 1: Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin
Arm 2: Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 105
-
At least ≥ 18 years of age (male or female) at the time of signing the informed consent form.
-
ECOG performance status of 0 to 1.
-
Patients with:
Phase 2 only:
• Advanced or metastatic NSCLC failing platinum-based therapy
Phase 3 only:
- Advanced or metastatic breast cancer, who have failed < 5 prior lines of chemotherapy (Note that study treatment may be the first chemotherapy treatment for advanced or metastatic cancer)
- locally advanced or metastatic NSCLC after platinum therapy failure
- HRPC (Note that study treatment may be the first chemotherapy treatment)
-
Pathology confirmation of cancer is required.
-
Patients with ≥ 1 of the following risk factors, at the initiation of docetaxel chemotherapy, that would require neutropenia prophylaxis per National Comprehensive Cancer Network (NCCN) guidelines (version 2, 2016):
- Prior chemotherapy or radiation treatment
- Bone marrow involvement by tumor
- Surgery and/or open wounds within 4 weeks of first administration of study drug
- Age > 65 years of age and receiving full chemotherapy dose intensity
-
Life expectancy of 3 months or more.
-
The following laboratory results assessed within 14 days prior to study drug administration:
- Hemoglobin >/= 9 g/dL independent of transfusion or growth factor support
- Absolute neutrophil count (ANC) >/= 1.5 x 10**9/L independent of growth factor support
- Serum total bilirubin </= 1.5 times the upper limit normal (ULN), unless the patient has a diagnosis of Gilbert's disease, in which case direct bilirubin </= 1.5 times ULN of the direct bilirubin.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 2.5 x ULN (</= 1.5 x ULN if alkaline phosphatase is > 2.5 x ULN)
- Serum creatinine </= 1.5 x ULN
Note: Results are from the central laboratory. Local laboratory results may be accepted on a case by case basis after discussion with the Medical Monitor, however in this case central laboratories must also be taken within the screening time window.
-
Prothrombin time (PT)/International Normalized Ratio (INR) ≤ 1.5 × upper limit of normal (ULN), activated partial thromboplastin time (PTT) ≤ 1.5 × ULN, based on central laboratory results.
-
Female subjects of childbearing potential have a negative pregnancy test at screening. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrhoeic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.
- Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
- Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) a vasectomized partner.
- For male patients who are sexually active and who are partners of premenopausal women: agreement to use two forms of contraception during the treatment period and for at least 3 months after the last dose of study drug.
-
History of myelogenous leukemia, myelodysplastic syndrome or concomitant sickle cell disease.
-
Received chemotherapy within 4 weeks prior to the first dose of study drug.
-
Received prior docetaxel treatment, except adjuvant docetaxel given > 1 year prior to first dose of study drug
-
Phase 3 only: Received >/= 5 lines of cytotoxic chemotherapy for advanced or metastatic breast cancer (adjuvant chemotherapy will count as one line of chemotherapy, and any hormonal or biological, non conjugate therapy [e.g., trastuzumab] will not count as a line of therapy).
-
Current use of strong cytochrome P450 (CYP) 3A4 inhibitors, within 3 days of the first administration of study drug, and 7 days after treatment with taxanes OR requires use of strong CYP3A4 inhibitors
-
Received an investigational agent or tumor vaccine within 2 weeks before the first dose of study drug; patients must have recovered from toxicity of prior treatment and have no > Grade 1 CTCAE (v4.03) treatment emergent AEs.
-
Receiving any concurrent anticancer therapies (except continued hormonal treatment).
-
Received a prior bone marrow or stem cell transplant.
-
Has a co-existing active infection or received systemic anti-infective treatment within 72 hours before the first dose of study drug.
-
Prior radiation therapy within the 4 weeks before the first dose of study drug.
-
Prior use of pegfilgrastim or filgrastim within 4 weeks before the first dose of study drug.
-
Presence of any serious or uncontrolled illness including, but not limited to: uncontrolled diabetes, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, uncontrolled arterial thrombosis, symptomatic pulmonary embolism, or psychiatric illness that would limit compliance with study requirements, or any other conditions that would preclude the patient from study treatment as per the discretion of the Investigator.
-
Significant cardiovascular history:
- History of myocardial infarction or ischemic heart disease within 1 year (within a window of up to 18 days less than 1 year) before first study drug administration;
- Uncontrolled arrhythmia;
- History of congenital QT prolongation;
- Electrocardiogram (ECG) findings consistent with active ischemic heart disease;
- New York Heart Association Class III or IV cardiac disease;
- Uncontrolled hypertension: blood pressure consistently >150 mm Hg systolic and > 100 mm Hg diastolic in spite of antihypertensive medication.
-
History of hemorrhagic diarrhea, inflammatory bowel disease, or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility.
-
Any other malignancy requiring active therapy.
-
Known human immunodeficiency virus (HIV) seropositivity.
-
Active Hepatitis B virus (HBV) infection which requires antiviral treatment. Patients with detectable Hepatitis B surface Antigen (HBsAg) may be eligible provided the patient has a negative viral load. Patients with a positive HBsAg must have a negative viral load before each chemotherapy administration. Hepatitis B surface antibody (anti HBs) without detectable HBsAg does NOT exclude patients from the study. Hepatitis C infection (Hepatitis C antibody reactive) which requires treatment also excludes patients from the study.
-
Female subject who is pregnant or lactating.
-
Unwilling or unable to comply with procedures required in this protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin D5W Placebo Arm 1 Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim Saline Placebo Arm 2 Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin Pegfilgrastim Arm 1 Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim Plinabulin Arm 2
- Primary Outcome Measures
Name Time Method Duration of Severe Neutropenia (DSN) 21 Days Duration of severe neutropenia (ANC \< 0.5 × 109/L)
- Secondary Outcome Measures
Name Time Method Change in Estimated Mean Bone Pain Score Day 1 through 8 in Cycle 1 (each cycle is 21 days) Change in estimated mean bone pain score from pre-dose Day 1 through Day 8. The bone pain scale assessment was based on the validated Wong-Baker Faces® Pain Rating Scale. The pain scale range is from 0 to 10. The severity of pain marked on a scale is from 0 ('no hurt') to 10 ('hurt worst').
Change in Patients With at Least 30% Platelet Count From Baseline in Cycle 1 Anytime during Cycle 1 (each cycle is 21 days) Patients with platelet count at least 30% change from baseline at any time during Cycle 1
Proportion of Patients With Neutrophil-to-lymphocyte Ratio (NLR) > 5 15 Days Proportion of patients with neutrophil-to-lymphocyte ratio (NLR) \> 5 from Day 1 through Day 15
Proportion of Patients With Thrombocytopenia 84 days Proportion of patients with thrombocytopenia (all grade) during 4 cycles
Infections 84 Days Incidence of infections in cycles 1 to 4
Antibiotic Use 21 Days Incidence of antibiotic use
Sepsis 84 Days To assess the incidence of sepsis
Trial Locations
- Locations (18)
Stanford University School of Medicine - Cancer Institute
🇺🇸Stanford, California, United States
Hematology/Oncology of the North Shore
🇺🇸Skokie, Illinois, United States
Heilongjiang Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Linyi Cancer Hospital
🇨🇳Linyi, China
Liaoning Cancer Hospital & Institute
🇨🇳Shenyang, China
Jiangsu Cancer Hospital
🇨🇳Nanjing, Jiangsu, China
State Budgetary Healthcare Institution of Stavropol Territory "Pyatigorsk Interregional Oncology Dispensary"
🇷🇺Pyatigorsk, Russian Federation
SBI of Healthcare "Oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region
🇷🇺Sochi, Russian Federation
Volgograd Regional Clinical Oncology Dispensary
🇷🇺Volgograd, Russian Federation
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Dnipropetrovsk City Multifunctional Hospital
🇺🇦Dnepropetrovsk, Ukraine
Prykarpatskiy Regional Oncological Center
🇺🇦Ivano-Frankivsk, Ukraine
Communal Institution of Kherson Regional Council "Kherson regional oncological dispensary"
🇺🇦Kherson, Ukraine
Kryvyi Rih Oncology Dispensary
🇺🇦Kryvyi Rih, Ukraine
Lviv State Oncological Regional Treatment and Preventive Center
🇺🇦Lviv, Ukraine
Municipal Institution "Sumy Regional Clinical Oncology Dispensary"
🇺🇦Sumy, Ukraine
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Beijing, China